InterCure Ltd. (INCR)
NASDAQ: INCR · Real-Time Price · USD
1.600
-0.080 (-4.76%)
Oct 10, 2025, 2:36 PM EDT - Market open
InterCure Revenue
InterCure had revenue of 113.11M ILS in the half year ending December 31, 2024, a decrease of -45.14%. This brings the company's revenue in the last twelve months to 243.12M, down -10.84% year-over-year. In the year 2024, InterCure had annual revenue of 238.85M, down -32.82%.
Revenue (ttm)
243.12M ILS
Revenue Growth
-10.84%
P/S Ratio
1.08
Revenue / Employee
759,759 ILS
Employees
320
Market Cap
78.27M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 238.85M | -116.71M | -32.82% |
Dec 31, 2023 | 355.55M | -33.13M | -8.52% |
Dec 31, 2022 | 388.68M | 169.01M | 76.93% |
Dec 31, 2021 | 219.68M | 154.64M | 237.78% |
Dec 31, 2020 | 65.04M | 56.11M | 628.60% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
INCR News
- 2 days ago - InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow - GlobeNewsWire
- 21 days ago - InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands - GlobeNewsWire
- 5 months ago - InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PRNewsWire
- 8 months ago - InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - PRNewsWire
- 10 months ago - InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PRNewsWire
- 1 year ago - Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
- 1 year ago - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewsWire
- 1 year ago - InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire